LYEL VS BLFS Stock Comparison

PerformanceTechnicalsEarningsProfitVolatilityAnalyst Price TargetsSentimentDividend
PerformanceTechnicalsEarningsProfitVolatilityAnalyst Price TargetsSentimentDividend

Performance

LYEL
10/100

LYEL returned -58.96% in the last 12 months. Based on SPY's performance of -13.12%, its performance is below average giving it a score of 10 of 100.

BLFS
10/100

BLFS returned -50.35% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Technicals

LYEL
54/100

LYEL receives a 53 of 100 based on 14 indicators. 7 are bullish, 6 are bearish.

BLFS
50/100

BLFS receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

Earnings

LYEL
100/100

LYEL has missed earnings 1 times in the last 20 quarters.

BLFS
10/100

BLFS has missed earnings 9 times in the last 20 quarters.

Profit

LYEL
10/100

Out of the last 15 quarters, LYEL has had 0 profitable quarters and has increased their profits year over year on 0 of them.

BLFS
28/100

Out of the last 20 quarters, BLFS has had 7 profitable quarters and has increased their profits year over year on 3 of them.

Volatility

LYEL
43/100

LYEL has had a lower than average amount of volatility over the last 12 months giving it a score of 43 of 100.

BLFS
51/100

BLFS has had a higher than average amount of volatility over the last 12 months giving it a score of 51 of 100.

Analyst Price Targets

LYEL

"Analyst Price Targets" not found for LYEL

BLFS
75/100

3 analysts offer 12-month price targets for BLFS. Together, they have an average target of 0, the most optimistic target put BLFS at 0 within 12-months and the most pessimistic has BLFS at 0.

Sentiment

LYEL

"Sentiment" not found for LYEL

BLFS
70/100

BLFS had a bullish sentiment score of 70.00% across Twitter and StockTwits over the last 12 months. It had an average of 2.72 posts, 0.11 comments, and 0.17 likes per day.

Dividend

LYEL

"Dividend" not found for LYEL

BLFS
22/100

BLFS's most recent dividend was $0.01 per share, based on a share price of $11.97. It was a payout ratio of 11.12% compared to their total earnings.

All score calculations are broken down here to help you make more informed investing decisions

Lyell Immunopharma, Inc. Common Stock Summary

Nasdaq / LYEL
Healthcare
Biotechnology
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

BioLife Solutions Inc. Summary

Nasdaq / BLFS
Healthcare
Medical - Instruments & Supplies
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.